All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the optimal use of asparaginase in adults with ALL?
Featured
Bookmark this article
The ALL Hub spoke to Wendy Stock, The University of Chicago, Chicago, US. We asked, What is the optimal use of asparaginase in adults with acute lymphoblastic leukemia (ALL)?
What is the optimal use of asparaginase in adults with ALL?
Firstly, Stock reviews the data on the outcomes of intensive asparaginase-containing regimens for younger adults with ALL; while they significantly improved outcomes, issues remained around dosing, obesity, and associated toxicities. For the remainder of the discussion, Stock highlights treatment approaches to reduce toxicities in the adult population, including capping the dose of pegylated-asparaginase at 3,750 units and reducing the dose further.
Stock concludes by emphasizing the importance of asparaginase as a key component for young adults with ALL, with ongoing measures being investigated to mitigate toxicities. A study in North America is currently investigating the use of L-carnitine to reduce hepatoxicities.
More about...
Your opinion matters
6 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox